Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Karl H, Link"'
Publikováno v:
World Journal of Surgery. 27:1075-1084
Adenocarcinoma of the pancreas is associated with the worst survival of any form of gastrointestinal malignancy. In spite of the progress in surgical treatment, resulting in increasing resection rates and a decrease in treatment-related morbidity and
Publikováno v:
World Journal of Surgery. 26:59-66
The objective of this study was to determine surgical morbidity and long-term outcome of colorectal cancer surgery for quality control reasons and as the basis for new treatment modalities. Surgically treated colorectal cancer patients (mean age 65 y
Autor:
Miriam Schatz, Frank Gansauge, Gerd Leder, Ludger Staib, Andrea Formentini, Hans G. Beger, J. Pillasch, Marko Kornmann, E. Sunelaitis, Karl H. Link
Publikováno v:
Cancer. 92:2746-2753
BACKGROUND Regional chemotherapy of isolated, nonresectable colorectal liver metastases (CRLMs) by hepatic artery infusion (HAI) has the advantages of high response rates and the possibility of downstaging and resection of CRLMs. 5-Fluorodeoxyuridine
Autor:
Peter V. Danenberg, Hans G. Beger, E. Sunelaitis, Jürgen Pillasch, Dennis Salonga, Karl H. Link, Gerd Leder, Marko Kornmann, Kathleen D. Danenberg, Urwe Butzer
Publikováno v:
Cancer. 89:288-296
BACKGROUND Patients with isolated, nonresectable liver tumors may receive regional hepatic arterial infusion (HAI) chemotherapy with response rates of about 50%. The objective of this study was to investigate the value of thymidylate synthase (TS) de
Publikováno v:
World Journal of Surgery. 23:946-949
The clinical benefit of adjuvant chemotherapy in pancreatic cancer patients is still questionable. Phase II studies using radiochemotherapy based on 5-fluorouracil (5-FU) provided evidence of an increase in median survival times. Because palliative c
Publikováno v:
Langenbeck's Archives of Surgery. 384:396-404
Background: In pancreatic cancer, multimodal protocols, involving chemotherapy, radiation, or regional treatment, are initiated to improve oncological outcome. Since pancreatic adenocarcinoma has been shown to be susceptible to immune stimulation, se
Autor:
N. Warszawski, Erwin M. Röttinger, Antje Warszawski, Manfred P. Lutz, Frank Gansauge, Bernd Michael Schneider, Karl H. Link
Publikováno v:
Strahlentherapie und Onkologie. 175:315-319
Behandlungsfaktoren zu identifizieren, die einen Einflus auf das Uberleben von Patienten mit Pankreaskarzinom haben. Patienten und Methode: In einer nichtrandomisierten Studie wurden 38 Patienten ausgewertet, die von 1984 bis 1998 wegen eines Adenoka
Publikováno v:
European Journal of Surgical Oncology (EJSO). 23:409-414
To improve the dismal prognosis of patients (pts) with pancreatic cancer we treated 32 patients with non-resectable (UICC III, 17 pts; UICC IV, 15 pts--group 1) and 20 patients with resected (UICC I, 1 pt; UICC II, 3 pts; UICC III, 16 pts--group 2) p
Publikováno v:
Der Chirurg. 68:874-880
Bei Patienten mit chronischer Pankreatitis ist der entzundliche Prozes im Pankreaskopf haufig Schrittmacher der Krankheit; der entzundliche Pankreaskopftumor verursacht das Schmerzsyndrom und fuhrt bei der Halfte der Patienten zu lokalen Komplikation
Autor:
Helmut Friess, John P. Neoptolemos, Claudio Bassi, Pat Baker, Paolo Pederzoli, Markus W. Büchler, Hans G. Beger, Christos Dervenis, Karl H. Link
Publikováno v:
Europe PubMed Central
Conclusion. The ESPAC-1 trial is the largest study of its kind in pancreatic cancer and should definitively address the question of the role of conventional methods of adjuvant treatment in pancreatic cancer. Background. At the joint International As